Role of budget impact in drug reimbursement decisions

Journal of Health Politics, Policy and Law

Volumn 33, Issue 2, 2008, Pages 225-247

  Cohen, Joshua Parsons ^a,c   Stolk, Elly ^b,d   Niezen, Maartje ^b,d  

^a TUFTS UNIVERSITY   (United States)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c Tufts Center for the Study of Drug Development (CSDD)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUDGET; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH ECONOMICS; MEDICAL DECISION MAKING; REIMBURSEMENT; REVIEW; UNCERTAINTY;

BUDGETS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION MAKING; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES;

EID: 41149155861     PISSN: 03616878     EISSN: 15271927     Source Type: Journal    
DOI: 10.1215/03616878-2007-054     Document Type: Review

References (56)

1. Aaron, H. J. 2003. Should Public Policy Seek to Control Growth of Health Care Spending? Web exclusive, Health Affairs, January 8. content.healthaffairs.org/cgi/reprint/ hlthaff.w3.28v1.
2. Agence national d'accréditation et d'evaluation en santé, n.d. Haute autorité de santé. www.anaes.fr (accessed November 23, 2005).
3. Anell, A. 2004. Priority Setting for Pharmaceuticals. European Journal of Health Economics 5:28-35.
4. Atkinson, A., and J. Stiglitz. 1980. Lectures on Public Economics. London: McGraw-Hill.
5. Baker, L., H. Birnbaum, J. Geppert, D. Mishol, and E. Moyneur. 2003. Relationship between Technology Availability and Health Care Spending. Web exclusive, Health Affairs, November 5. content.healthaffairs.org/cgi/ reprint/hlthaff.w3.537v1.
6. Birch, S., and A. Gafni. 2006. Information Created to Evade Reality (ICER). PharmacoEconomics 24:1121-1131.
7. Bleichrodt, H., E. Diecidue, and J. Quiggin. 2004. Equity Weights in the Allocation of Health Care: The Rank-Dependent QALY Model. Journal of Health Economics 23:157-171.
8. Cabanilla, L., and M. Romme. 2004. Aequus et efficiens: Bias Groupings and Characteristics of the Health-Related Social Welfare Function. Department of Health Economics thesis project, Erasmus University, Rotterdam, the Netherlands.
9. Chang, J., and J. Sung. 2005. Health Plan Budget Impact Analysis for Pimecrolimus. Journal of Managed Care Pharmacy 11:66-73.
10. Coast, J. 2004. Is Economic Evaluation in Touch with Society's Health Values? BMJ 329:1233-1236.
11. Cohen, J., E. Stolk, and M. Niezen. 2007. The Increasingly Complex Fourth Hurdle for Pharmaceuticals. PharmacoEconomics 25 (9): 727-734.
12. Crowley, J., D. Asher, and L. Elam. 2003. Medicaid Outpatient Prescription Drug Benefits: Findings from a National Survey, 2003. December, www.kff.org/medicaid/upload/Medicaid-Outpatient-Prescription-Drug-Benefits- Findings-from -a-National-Survey-2003.pdf.
13. Culyer, A. 1990. Commodities, Characteristics of Commodities, Characteristics of People, Utilities, and the Quality of Life. In Quality of Life, ed. S. Baldwin, C. Godfrey, and C. Propper, 9-27. London: Routledge.
14. Cutler, D., and M. McClellan. 2001. Is Technological Change in Medicine Worth It? Health Affairs 20 (3): 11-29.
15. Department of Health (England). 2002. Cost Effective Provision of Disease Modifying Therapies for People with Multiple Sclerosis. February 4. www.dh.gov.uk/assetRoot/04/01/22/14/04012214.pdf.
16. Devlin, N., and D. Parkin. 2004. Does NICE Have a Cost-Effectiveness Threshold and What Other Factors Influence Its Decisions? A Binary Choice Analysis. Health Economics 13:437-452.
17. Dolan, P. 1998. The Measurement of Individual Utility and Social Welfare. Journal of Health Economics 17:39-52.
18. Eichler, H. G., S. Kong, W. Gerth, M. Panagiotis, and B. Jonsson. 2004. Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? Value in Health 7:518-528.
19. Elbasha, E., and M. Messonnier. 2004. Cost-Effectiveness Analysis and Health Care Resource Allocation: Decision Rules under Variable Returns to Scale. Health Economics 13:21-35.
20. Epstein, D., Z. Chalabi, K. Claxton, and M. Sculpher. 2005. Mathematical Programming for the Optimal Allocation of Health Care Resources. April 20. www.york.ac.uk/inst/che/pdf/mathprog.pdf.
21. Fox, P., and A. Oxman. 2001. Informing Judgment: Case Studies from Six Countries. September. www.milbank.org/2001cochrane/010903cochrane.html.
22. Gafni, A., and S. Birch. 2006. Incremental Cost-Effectiveness Ratios (ICERs): The Silence of the Lambda. Social Science and Medicine 62:2091-2100.
23. Gandjour, A., and K. Lauterbach. 2003. Utilitarian Theories Reconsidered: Common Misperceptions, More Recent Developments, and Health Policy Implications. Health Care Analysis 11:229-244.
24. George, B., A. Harris, and A. Mitchell. 2001. Cost-Effectiveness Analysis and the Consistency of Decision Making: Evidence from Pharmaceutical Reimbursement in Australia (1991 to 1996). PharmacoEconomics 19:1103-1109.
25. Gray, A. 2005. Population Ageing and Health Care Expenditure. Ageing Horizons, no. 2:15-20. www.ageing.ox.ac.uk/ageinghorizons/thematic%20issues/ healthcare/papers%20healthcare/pdf%20files/gray%20issue%202%202005.pdf.
26. Harding, A. 2002. Using Microsimulation Models in the Policy Process in an Ageing Society. Paper presented at Modelling Policy in an Ageing Europe, conference at London School of Economics, January 11.
27. Harris, A., M. Buxton, B. O'Brien, F. Rutten, and M. Drummond. 2001. Using Economic Evidence in Reimbursement Decisions for Health Technologies: Experience of Four Countries. Expert Review of Pharmacoeconomics and Outcomes Research 1:7-12. www.future-drugs.com/doi/pdf/10.1586/14737167.1.1.7.
28. Hughes, D., B. Tunnage, and S. Yeo. 2005. Drugs for Exceptionally Rare Diseases: Do They Deserve Special Status for Funding? QJM 98:829-836.
29. Kooijman, H. 2003. Zorg Verzekerd: Internationaal vergelijkend onderzoek naar de samenstelling van het basispakket van de nationale ziektekostenverzekering [International Comparative Analysis of National Health Care Benefits] PharMerit (white paper).
30. Koopmanschap, M., and F. Rutten. 2003. The Drug Budget Silo Mentality: The Dutch Case. Value in Health 6:46-51.
31. Le Pen, C. 2003. The Drug Budget Silo Mentality: The French Case. Value in Health 6:S10-S19.
32. Luijn, J. V. 1999. CFH-rapport 99/05 Clopidogrel. December 16. www.cvz.nl/resources/cfh9905%20verzamel%20rapport_tcm28-21251.pdf.
33. Mauskopf, J., S. Sullivan, L. Annemans, J. Caro, C. D. Mullins, M. Nuijten, E. Orlewska, et al. 2006. Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices-Budget Impact Analysis. Value in Health 10. www.ispor.org/workpaper/ budget_impact.asp (accessed May 1, 2007).
34. Mossialos, E., M. Mrazek, and F. Walley, eds. 2004. Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity, and Quality. Maidenhead, England: Open University Press.
35. Neumann, P., E. Sandberg, C. Bell, P. Stone, and R. Chapman. 2000. Are Pharmaceuticals Cost-Effective? A Review of Evidence. Health Affairs 19 (2): 92-109.
36. Niezen, M., and M. van der Zwet. 2005. Evaluatie van Bijlage 2 als beleidsinstrument [Evaluation of Annex 2 as Policy Tool]. Working Paper. Rotterdam: Erasmus University Institute of Health Policy and Management.
37. Organisation for Economic Co-operation and Development (OECD) Health Policy Unit. 2002. OECD Health Data 2002. www.oecd.org/document/22/0,2340, en_2649_34631_1935190_1_1_1_1,00.html.
38. Oostenbruggen, M., R. Jansen, K. Mur, and H. Kooijman. 2005. Penny and Pound Wise: Pharmacoeconomics from a Governmental Perspective. PharmacoEconomics 23:219-226.
39. Orlewska, E., and P. Mierzejewski. 2004. Proposal of Polish Guidelines for Conducting Financial Analysis and Their Comparison to Existing Guidance on Budget Impact in Other Countries. Value in Health 7:1-10.
40. Rawls, J. 1971. A Theory of Justice. Cambridge, MA: Belknap Press, Harvard University Press.
41. Sculpher, M., and K. Claxton. 2005. Establishing the Cost-Effectiveness of New Pharmaceuticals under Conditions of Uncertainty - When Is There Sufficient Evidence? Value in Health 8:433-446.
42. Sendi, P., and A. Gafni. 2003. The HAART Side of Resource Allocation. Canadian Medical Association Journal 169:120-121.
43. Smith, C., C. Cowan, S. Heffler, and A. Catlin. 2006. National Health Spending in 2004: Recent Slowdown Led by Prescription Drug Spending. Health Affairs 25:186-196.
44. Sorensen, J., and L. Andersen. 2005. The Case of Tumour Necrosis Factor-α Inhibitors in the Treatment of Rheumatoid Arthritis: A Budget Impact Analysis. PharmacoEconomics 23:289-298.
45. Spooner, J., P. Gandhi, and S. B. Connelly. 2007. AMCP Format Dossier Requests: Manufacturer Response and Formulary Implications for One Large Health Plan. Journal of Managed Care Pharmacy 13:37-43.
46. Stolk, E., W. Brouwer, and J. Busschbach. 2002. Rationalising Rationing: Economic and Other Considerations in the Debate about Funding of Viagra. Health Policy 59:53-63.
47. Stolk, E., and F. Rutten. 2005. The Health Basket in the Netherlands. European Journal of Health Economics 6:53-57.
48. Syrett, K. 2003. A Technocratic Fix to the "Legitimacy Problem"? The Blair Government and Health Care Rationing in the United Kingdom. Journal of Health Politics, Policy and Law 28:715-746.
49. Taylor, R., M. Drummond, G. Salkfeld, and S. Sullivan. 2004. Inclusion of Cost Effectiveness in Licensing Requirements of New Drugs: The Fourth Hurdle. BMJ 329:972-975.
50. Towse, A. 2003. The Efficient Use of Pharmaceuticals: Does Europe Have Any Lessons for a Medicare Drug Benefit? Health Affairs 22 (3): 42-45.
51. Wang, Z., J. Salmon, and S. Walton. 2004. Cost-Effectiveness Analysis and the Formulary Decision-Making Process. Journal of Managed Care Pharmacy 10:48-59.
52. Weinstein, M. 1988. A QALY Is a QALY - Or Is It? Journal of Health Economics 7:289-290.
53. Williams, I., S. Bryan, and S. McIver. 2006. The Use of Economic Evaluations in NHS Decision-Making. August. www.pcpoh.bham.ac.uk/publichealth/ nccrm/PDFs_and_documents/Publications/Williams_et_al_Final_report.pdf.
54. Zaric, G., and B. O'Brien. 2005. Analysis of a Pharmaceutical Risk Sharing Agreement Based on the Purchaser's Total Budget. Health Economics 14:793-803.
55. Zivin, J. G. 2001. Cost-Effectiveness Analysis with Risk Aversion. Health Economics 10:499-508.
56. Zöllner, H., G. Stoddart, and C. S. Smith. 2003. Learning to Live with Health Economics. www.euro.who.int/document/ffa/hlth_econ_ch3.pdf (accessed December 10, 2006).